Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR - PubMed (original) (raw)
Review
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Anna C Calkin et al. Nat Rev Mol Cell Biol. 2012.
Abstract
Nuclear receptors are integrators of hormonal and nutritional signals, mediating changes to metabolic pathways within the body. Given that modulation of lipid and glucose metabolism has been linked to diseases including type 2 diabetes, obesity and atherosclerosis, a greater understanding of pathways that regulate metabolism in physiology and disease is crucial. The liver X receptors (LXRs) and the farnesoid X receptors (FXRs) are activated by oxysterols and bile acids, respectively. Mounting evidence indicates that these nuclear receptors have essential roles, not only in the regulation of cholesterol and bile acid metabolism but also in the integration of sterol, fatty acid and glucose metabolism.
Figures
Figure 1. Mechanism of action of LXR and FXR
a | The basic structure of a nuclear receptor, highlighting the DNA-binding and ligand-binding domains. b | Liver X receptor (LXR) forms an obligate heterodimer with retinoid X receptor (RXR) that binds to a DR4 (direct repeat spaced by four nucleotides) LXRE (LXR response element) in the regulatory regions of target genes, thereby repressing gene expression. Following ligand binding to LXR or RXR, the heterodimer changes conformation, which leads to the release of co-repressors and the recruitment of co-activators. This results in the transcription of target genes. Similarly, farnesoid X receptor (FXR) forms a heterodimer with RXR and binds to the FXR response element (FXRE), which is typically an inverse repeat spaced by one nucleotide (IR1), in its target genes to induce gene expression. AF domain, activation function domain; C-terminal, carboxy-terminal; N-terminal, amino-terminal.
Figure 2. Coordinated effects of LXR on metabolism
Liver X receptor (LXR) mediates effects on multiple metabolic pathways in a tissue-specific manner. In peripheral cells such as macrophages, LXR induces expression of IDOL (inducible degrader of the low-density lipoprotein receptor (LDLR)), which promotes the proteasome-mediated degradation of LDLR and thus results in reduced LDL uptake into the cell. In peripheral cells, LXR also increases ARL7 (ADP-ribosylation factor-like 7), ABCA1 (ATP-binding cassette transporter A1) and ABCG1 expression, promoting the movement of cholesterol to the plasma membrane and cholesterol efflux and transfer to lipid-poor molecules such as apolipoprotein AI (APOAI) and pre-β high-density lipoprotein (HDL), thus increasing plasma HDL levels. APOE promotes the return of HDL to the liver. Furthermore, in the liver, LXR promotes cholesterol conversion to bile acids by cytochrome P450 7A1 (CYP7A1). It also promotes fatty acid synthesis via induction of sterol-regulatory element-binding protein 1C (SREBP1C) and its targets, fatty acid synthase (FAS), acetyl CoA carboxylase (ACC) and steroyl CoA desaturase 1 (SCD1). Secretion of triglyceride-rich very low-density lipoproteins (VLDLs) by the liver transports lipids to peripheral tissues, including adipose tissue, where the action of lipoprotein lipase (LPL) liberates fatty acids from VLDL. In adipose tissue, LXR regulates the expression of lipid-binding and metabolic proteins such as APOD and SPOT14 and may promote the breakdown of fatty acids through their β-oxidation (which occurs in mitochondria). LXR also promotes glucose uptake via induction of glucose transporter type 4 (GLUT4). Finally, in the intestine, LXR inhibits cholesterol absorption by inducing the expression of the ABC transporters ABCG5 and ABCG8 and possibly ABCA1.
Figure 3. Coordinated effects of FXR on metabolism
Farnesoid X receptor (FXR) mediates effects on multiple metabolic pathways in a tissue-specific manner. In the liver, FXR reduces conversion of cholesterol to bile acids by downregulating the expression of enzymes involved in bile acid synthesis, such as cytochrome P450 7A1 (CYP7A1) and CYP8B1. FXR also reduces bile acid toxicity in the liver by increasing other bile acid-modifying enzymes including sulphotransferase 2A1 (SULT2A1), UDP-glucuronosyltransferase 2B4 (UGT2B4) and CYP3A4. Bile acids are conjugated to either glycine or taurine before secretion into the bile; FXR enhances bile acid conjugation by increasing the expression of bile acid CoA synthase (BACS) and bile acid CoA–amino acid _N_-acetyltransferase (BAAT), and FXR promotes the transport of bile acids to the gall bladder via bile salt export pump (BSEP), multidrug resistance protein 2 (MDR2) and MDR3 (membrane transport proteins are depicted as ovals). Within the intestine, FXR reduces bile acid absorption via downregulation of the apical sodium-dependent bile acid transporter (ASBT), promotes bile acid movement across the enterocyte via ileal bile acid binding-protein (IBABP) and promotes recycling of bile acids to the liver via organic solute transporter-α (OSTα) and OSTβ. In addition, FXR reduces hepatic uptake of bile acids by reducing the expression of organic anion transporting polypeptide (OATP) and sodium taurocholate cotransporting polypeptide (NTCP). FXR also promotes the release of fibroblast growth factor 15 (FGF15) in mice or FGF19 in humans from the intestine. FGF15 or FGF19 travel to the liver, acting on FGF4 receptor (FGF4R) to reduce CYP7A1 expression and thus repress bile acid synthesis. In the liver, FXR also acts on glucose metabolism by reducing gluconeogenesis via the downregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), two key enzymes in the glucose synthesis pathway. Futhermore, FXR reduces lipogenesis via inhibition of sterol-regulatory element-binding protein 1C (SREBP1C) and fatty acid synthase (FAS).
Similar articles
- Functions of Cholesterol Metabolites.
Sato R. Sato R. J Nutr Sci Vitaminol (Tokyo). 2015;61 Suppl:S151-3. doi: 10.3177/jnsv.61.S151. J Nutr Sci Vitaminol (Tokyo). 2015. PMID: 26598835 - Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Wójcicka G, Jamroz-Wiśniewska A, Horoszewicz K, Bełtowski J. Wójcicka G, et al. Postepy Hig Med Dosw (Online). 2007 Dec 3;61:736-59. Postepy Hig Med Dosw (Online). 2007. PMID: 18063918 Review. - LXRS and FXR: the yin and yang of cholesterol and fat metabolism.
Kalaany NY, Mangelsdorf DJ. Kalaany NY, et al. Annu Rev Physiol. 2006;68:159-91. doi: 10.1146/annurev.physiol.68.033104.152158. Annu Rev Physiol. 2006. PMID: 16460270 Review. - Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home?
Ory DS. Ory DS. Circ Res. 2004 Oct 1;95(7):660-70. doi: 10.1161/01.RES.0000143422.83209.be. Circ Res. 2004. PMID: 15459087 Review. - Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.
Fiévet C, Staels B. Fiévet C, et al. Biochem Pharmacol. 2009 Apr 15;77(8):1316-27. doi: 10.1016/j.bcp.2008.11.026. Epub 2008 Dec 3. Biochem Pharmacol. 2009. PMID: 19101522 Review.
Cited by
- Role of Gut Microbial Metabolites in Cardiovascular Diseases-Current Insights and the Road Ahead.
Datta S, Pasham S, Inavolu S, Boini KM, Koka S. Datta S, et al. Int J Mol Sci. 2024 Sep 23;25(18):10208. doi: 10.3390/ijms251810208. Int J Mol Sci. 2024. PMID: 39337693 Free PMC article. Review. - The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications.
Luo Z, Zhou W, Xie T, Xu W, Shi C, Xiao Z, Si Y, Ma Y, Ren Q, Di L, Shan J. Luo Z, et al. Acta Pharm Sin B. 2024 Aug;14(8):3385-3415. doi: 10.1016/j.apsb.2024.04.027. Epub 2024 May 3. Acta Pharm Sin B. 2024. PMID: 39220868 Free PMC article. Review. - Polyphenols alleviate metabolic disorders: the role of ubiquitin-proteasome system.
Gu W, Wu G, Chen G, Meng X, Xie Z, Cai S. Gu W, et al. Front Nutr. 2024 Aug 12;11:1445080. doi: 10.3389/fnut.2024.1445080. eCollection 2024. Front Nutr. 2024. PMID: 39188976 Free PMC article. Review. - Epigenetic programming of host lipid metabolism associated with resistance to TST/IGRA conversion after exposure to Mycobacterium tuberculosis.
Dill-McFarland KA, Simmons JD, Peterson GJ, Nguyen FK, Campo M, Benchek P, Stein CM, Vaisar T, Mayanja-Kizza H, Boom WH, Hawn TR. Dill-McFarland KA, et al. mSystems. 2024 Sep 17;9(9):e0062824. doi: 10.1128/msystems.00628-24. Epub 2024 Aug 20. mSystems. 2024. PMID: 39162406 Free PMC article. - Nuclear Receptors and the Hidden Language of the Metabolome.
Chen Y, Anderson MT, Payne N, Santori FR, Ivanova NB. Chen Y, et al. Cells. 2024 Jul 31;13(15):1284. doi: 10.3390/cells13151284. Cells. 2024. PMID: 39120315 Free PMC article. Review.
References
- Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121–141. - PubMed
- Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature. 1996;383:728–731. [This study identified oxysterols as endogenous ligands for LXR.] - PubMed
- Parks DJ, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368. [The first demonstration that bile acids are endogenous ligands for FXR.] - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- HL066088/HL/NHLBI NIH HHS/United States
- HL030568/HL/NHLBI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R01 HL066088/HL/NHLBI NIH HHS/United States
- P01 HL030568/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources